Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × INDUSTRY × iscalimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

Carboplatin 268 Paclitaxel 266 Gemcitabine 241 Bevacizumab 225 Cisplatin 215 pembrolizumab 211 Docetaxel 208 Pemetrexed 159 Capecitabine 147 Fluorouracil 128 Cyclophosphamide 120 Oxaliplatin 119 Nivolumab 112 Dexamethasone 99 Trastuzumab 88 Leucovorin 86 Cetuximab 83 Rituximab 82 Irinotecan 82 Injections 75 Erlotinib Hydrochloride 70 Prednisone 68 Doxorubicin 68 Temozolomide 67 atezolizumab 65 Ipilimumab 64 Bortezomib 64 Fulvestrant 59 Radiotherapy 54 Drug Therapy 51

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02565576 2021-01-05

Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis

Novartis

Phase 2 Completed

44 enrolled 17 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡